article thumbnail

Gut bacteria could be behind weaker immune responses to COVID-19 vaccine

Medical Xpress

Gut bacteria that break down a sugar called fucose could be dampening our immune response to the COVID-19 mRNA vaccine, according to a study led by researchers from the Okinawa Institute of Science and Technology (OIST).

article thumbnail

Commensal bacteria ‘vaccine’ may safely prep immune cells for meningitis-causing cousin

Scienmag

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Research Shows How Gut Bacteria Can Help Fight Cancer

XTalks

Increasing research into the gut microbiome has revealed new and emerging roles for the ‘good bacteria’ in our bodies, with the latest being a new study that shows how they can help the immune system attack cancer cells. Related: Characterizing the Tumor Microbiome: Bacteria Found in Tumors May Predict Response to Therapy.

article thumbnail

Infant antibiotic exposure can affect future immune responses toward allergies

Scienmag

Early life exposure to antibotics in utero and through mother’s milk disrupts beneficial gut bacteria, compromising T-cell development, Rutgers research shows Exposure to antibiotics in utero and infancy can lead to an irreversible loss of regulatory T-cells in the colon-a valuable component of the immune system’s response toward allergens (..)

article thumbnail

Gum disease may lie at the root of some arthritis flareups

Medical Xpress

But new research may help explain this link between gum disease and an otherwise disparate condition. It's a well-documented medical mystery: Patients with gum disease are less likely to respond to rheumatoid arthritis treatments.

article thumbnail

Novo Nordisk Foundation establishes new vaccine initiative worth $260m

Pharma Times

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. Airborne diseases, such as COVID-19, chickenpox and respiratory syncytial virus, occur when bacteria or viruses are transmitted through small respiratory droplets.

article thumbnail

Harnessing the microbiome: The new frontier in drug discovery and testing 

Drug Discovery World

Paul Denslow , CEO, Intus Bio, discusses how a new approach to tracking gut bacteria can revolutionse our understanding of the microbiome and bring about new discoveries for therapeutics. It’s a long-held doctrine that there’s no effective method to track the microbiome during drug research and development.